PAVmed Inc. Series Z Warrant - PAVMZ STOCK NEWS

Lucid Diagnostics reported Q3 2024 financial results with EsoGuard® revenue of $1.2M, showing a 20% sequential increase from Q2 and 50% annual growth. The company performed 2,787 commercial EsoGuard tests in Q3, with October setting a single-month record of over 1,400 tests. Operating expenses were $12.9M, resulting in a GAAP net loss of $12.4M or $(0.25) per share. Cash position stood at $14.5M as of September 30, 2024. The company has secured agreements for $21.75M in Senior Secured Convertible Notes and expects to increase its cash runway by approximately $13.2M after redemption of existing notes.

PAVmed (Nasdaq: PAVM, PAVMZ), a commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for November 14, 2024, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will discuss company operations and growth strategy, while President and CFO Dennis McGrath will present third quarter 2024 financial results.

U.S. callers can join via 1-800-836-8184, while international participants should dial 1-646-357-8785. The webcast will be accessible through the company's investor relations website at pavmed.com, with a 30-day replay available afterward.

PAVmed Inc. (NASDAQ: PAVM) provided a business update and Q2 2024 financial results. Key highlights include:

• Lucid reported record quarterly EsoGuard® test volume of 3,147, up 31% from Q1
• EsoGuard revenue was $1.0 million, up 514% year-over-year
• Veris Health launched a pilot program with The Ohio State's James Cancer Hospital
• Q2 operating expenses were $14.6 million
• GAAP net loss was $10.9 million or $(1.19) per share
• Non-GAAP adjusted loss was $7.7 million or $(0.84) per share
• Cash and equivalents of $25.5 million as of June 30, 2024

The company is focused on strengthening finances by making subsidiaries independently financeable. Lucid remains PAVmed's strongest asset, while Veris Health and PortIO are pursuing independent financing.

Lucid Diagnostics Inc. (NASDAQ: LUCD) reported its Q2 2024 financial results and business update. Key highlights include:

- EsoGuard® test volume increased 31% quarterly and 44% annually
- EsoGuard revenue was $1.0M, flat compared to Q1 but up 514% year-over-year
- 3,147 commercial EsoGuard tests performed, a single-quarter record
- Positive clinical data released from ENVET-BE and ESOGUARD BE-1 studies
- Cash and cash equivalents of $24.9M as of June 30, 2024
- GAAP net loss of $11.0M or $(0.23) per share
- Non-GAAP adjusted loss of $9.7M or $(0.20) per share

The company is focused on securing broad coverage and reimbursement to drive EsoGuard revenue growth.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a diversified commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for August 13, 2024, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will provide an overview of the company's operations and growth strategy, while President and CFO Dennis McGrath will discuss second quarter 2024 financial results.

Investors can access the webcast through PAVmed's website or join the conference call by dialing 1-800-836-8184 (U.S.) or 1-646-357-8785 (international). The call name is "PAVmed Business Update". A 30-day replay will be available on the company's website following the call.

PAVmed (NASDAQ: PAVM) provided a business update and reported financial results for Q1 2024. The company held a webcast on May 14, 2024, to discuss the results. Lucid Diagnostics, a subsidiary, completed a $29.8 million Series B offering, securing key reimbursement milestones. Veris Health signed an MOU with The Ohio State's James Cancer Hospital. Financially, PAVmed reported $1.0 million in EsoGuard revenues, flat quarter-over-quarter but a 124% increase from Q1 2023. Operating expenses were $15.0 million with a GAAP net loss of $22.8 million. Cash reserves stood at $25.5 million as of March 31, 2024.

Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, provided a business update and financial results for the first quarter of 2024. The company reported a 10% increase in EsoGuard test volume, a strengthened balance sheet after a $29.8 million Series B Preferred Stock Offering, and a MolDX pre-submission meeting scheduled for July 17, 2024. Lucid also highlighted revenue growth, clinical study outcomes, and market access strategy.

Lucid Diagnostics Inc. announced that the EsophaCap sponge-on-a-string esophageal cell collection device has been subjected to a Class II FDA recall due to serious device failures reported. Lucid's EsoCheck® remains unaffected by the recall and continues to be the gold standard for non-endoscopic cell collection. The recall stemmed from two serious device failures reported in a recent publication of one of the studies using the EsophaCap device. Lucid's EsoCheck® is a modern technology enabling precise, targeted cell collection for esophageal precancer testing, offering unprecedented early precancer detection without causing any serious adverse events.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will host a business update conference call and webcast on May 14, 2024, at 8:30 AM ET. During the call, PAVmed's CEO will provide an overview of operations and growth strategy, while the CFO will discuss the first quarter 2024 financial results.